Mutational and expression analysis of the NF1 gene argues against a role as tumor suppressor in sporadic pilocytic astrocytomas

Journal of Neuropathology and Experimental Neurology

Volumn 61, Issue 10, 2002, Pages 896-902

  Wimmer, Katharina ^a   Eckart, Markus ^a   Meyer Puttlitz, Birgit ^a   Fonatsch, Christa ^a   Pietsch, Torsten ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Loss of heterozygosity (LOH); Mutations; Neurofibromatosis type I; Pilocytic astrocytomas; Real time PCR

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; ASTROCYTOMA; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; GENE MUTATION; GENETIC TRANSCRIPTION; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; MALE; NEUROFIBROMATOSIS; NF1 GENE; OPTIC NERVE GLIOMA; PILOCYTIC ASTROCYTOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCHOOL CHILD; TUMOR SUPPRESSOR GENE;

EID: 0036795292     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/61.10.896     Document Type: Article

References (41)

1. Riccardi V. Neurofibromatosis: Phenotype, natural history, and pathogenesis. (2nd. edition). Baltimore: Johns Hopkins University Press, 1992
2. Huson S, Hughes R. The neurofibromatoses: A clinical and pathogenetic overview. London: Chapman and Hull, 1994
3. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. Jama 1997;278:51-57
4. Serra E, Puig S, Otero D, et al. Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. Am J Hum Genet 1997; 61:512-19
5. Legius E, Marchuk DA, Collins FS, Glover TW. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet 1993;3:122-26
6. Colman SD, Williams CA, Wallace MR. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nat Genet 1995;11:90-92
7. Bollag G, McCormick F. Ras regulation. NF is enough of GAP. Nature 1992;356:663-64
8. Nishi T, Lee PS, Oka K, et al. Differential expression of two types of the neurofibromatosis type 1 (NF1) gene transcripts related to neuronal differentiation. Oncogene 1991;6:1555-59
9. Suzuki Y, Suzuki H, Kayama T, Yoshimoto T, Shibahara S. Brain tumors predominantly express the neurofibromatosis type 1 gene transcripts containing the 63 base insert in the region coding for GTPase activating protein-related domain. Biochem Biophys Res Commun 1991;181:955-61
10. Gutmann DH, Geist RT, Wright DE, Snider WD. Expression of the neurofibromatosis 1 (NF1) isoforms in developing and adult rat tissues. Cell Growth Differ 1995;6:315-23
11. Andersen LB, Ballester R, Marchuk DA, et al. A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity. Mol Cell Biol 1993;13:487-95
12. Kluwe L, Hagel C, Tatagiba M, et al. Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. J Neuropathol Exp Neurol 2001;60:917-20
13. Gutmann DH, Donahoe J, Brown T, James CD, Perry A. Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. Neuropathol Appl Neurobiol 2000;26:361-67
14. Gutmann DH, Loehr A, Zhang Y, Kim J, Henkemeyer M, Cashen A. Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation. Oncogene 1999; 18:4450-59
15. Gutmann DH, Wu YL, Hedrick NM, Zhu Y, Guha A, Parada LF Heterozygosity for the neurofibromatosis 1 (NF1) tumor suppressor results in abnormalities in cell attachment, spreading and motility in astrocytes. Hum Mol Genet 2001;10:3009-16
16. Lau N, Feldkamp MM, Roncari L, et al. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol 2000;59:759-67
17. Russell D, Rubinstein L. Pathology of tumours of the nervous system. Baltimore: Williams and Wilkins, 1989
18. von Deimling A, Louis DN, Menon AG, et al. Deletions on the long arm of chromosome 17 in pilocytic astrocytoma. Acta Neuropathol 1993;86:81-85
19. Sanoudou D. Tingby O, Ferguson-Smith MA, Collins VP, Coleman N. Analysis of pilocytic astrocytoma by comparative genomic hybridization. Br J Cancer 2000;82:1218-22
20. Platten M, Giordano MJ, Dirven CM, Gutmann DH, Louis DN. Up-regulation of specific NF 1 gene transcripts in sporadic pilocytic astrocytomas. Am J Pathol 1996;149:621-27
21. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61:215-25; commentary 226-29
22. Albrecht S, von Deimling A, Pietsch T, et al. Microsatellite analysis of loss of heterozygosity on chromosomes 9q, 11p and 17p in medulloblastomas. Neuropathol Appl Neurobiol 1994;20:74-81
23. Heim RA, Kam-Morgan LNW, Binnie CG, et al. Distribution of 13 truncating mutations in the neurofibromatosis 1 gene. Hum Mol Genet 1995;4:975-81
24. Lázaro G, Gaona A, Xu G, Weiss R, Estevill X. A highly informative CA/GT repeat polymorphism in intron 38 of the human neurofibromatosis type 1 (NF1) gene. Hum Genet 1993;92:429-30
25. Lázaro G, Gaona A, Estevill X. Two CA/GT repeat polymorphisms in intron 27 of the human neurofibromatosis type 1 (NF1) gene. Hum Genet 1994;93:351-52
26. Hoffmeyer S, Assum G. An RsaI polymorphism in the transcribed region of the neurofibromatosis (NF1)-gene. Hum Genet 1994;93: 481-82
27. Budowle B, Chakraborty R, Giusti AM, Eisenberg AJ, Allen RC. Analysis of the VNTR locus D1S80 by the PCR followed by high-resolution PAGE. Am J Hum Genet 1991;48:137-44
28. Medhurst AD, Lezoualc'h F, Fischmeister R, Middlemiss DN, Sanget GJ. Quantitative mRNA analysis of five C-terminal splice variants of the human 5-HT4 receptor in the central nervous system by TaqMan real time RT-PCR. Brain Res Mol Brain Res 2001;90: 125-34
29. Vandenbroucke II, Vandesompele J, Paepe AD, Messiaen L. Quantification of splice variants using real-time PCR. Nucleic Acids Res 2001;29:E68-68
30. Messiaen L, Callens T, Mortier G, et al. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mut 2000;15:541-55
31. Eisenbarth I, Beyer K, Krone W, Assum G. Toward a survey of somatic mutations of the NF1 gene in benign neurofibromas of patients with neurofibromatosis type 1. Am J Hum Genet 2000;66: 393-401
32. Gutmann DH, Giordano MJ, Mahadeo DK, Lau N, Silbergeld D, Guha A. Increased neurofibromatosis 1 gene expression in astrocytic tumors: Positive regulation by p21-ras. Oncogene 1996;12: 2121-27
33. Gutmann DH, Tennekoon GI, Cole JL, Collins FS, Rutkowski JL. Modulation of the neurofibromatosis type 1 gene product, neurofibromin, during Schwann cell differentiation. J Neurosci Res 1993; 36:216-23
34. Tokuyama T, Uemura K, Fujita M. The two types of mRNAs for neurofibromin isoforms produced by von Recklinghausen neurofibromatosis (NF1) gene: Analysis in human astrocytic tumors. Neurosci Lett 1995;196:189-92
35. Aaltonen V, Bostrom PJ, Soderstrom KO. et al. Urinary bladder transitional cell carcinogenesis is associated with down-regulation of NF1 tumor suppressor gene in vivo and in vitro. Am J Pathol 1999;154:755-65
36. Gutmann DH, Geist RT, Rose K, Wallin G, Moley JE Loss of neurofibromatosis type I (NF1) gene expression in pheochromocytomas from patients without NF1. Genes Chromosomes Cancer 1995;13:104-9
37. lyengar TD, Ng S, Lau CC, et al. Differential expression of NF1 type I and type II isoforms in sporadic borderline and invasive epithelial ovarian tumors. Oncogene 1999;18:257-62
38. Uchida T, Matozaki T, Suzuki T, et al. Expression of two types of neurofibromatosis type I gene transcripts in gastric cancers and comparison of GAP activities. Biochem Biophys Res Commun 1992;187:332-39
39. Lie YS, Petropoulos CJ. Advances in quantitative PCR technology: 5′ nuclease assays. Curr Opin Biotechnol 1998;9:43-48
40. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996;6:986-94
41. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000;25:169-93